Novartis Withdraws Its Application To Extend The Marketing Authorisation For Glivec
Sat, 28 Oct 2006 12:00 PM EST
... The European Medicines Agency has been formally notified by Novartis Europharm Ltd of its decision to withdraw its application for a change to the marketing authorisation for Glivec (imatinib mesilate) 50 mg and 100 mg capsules and 100 mg and 400 mg film-coated tablets. [click link for full article] ...
Related Topics
- Hepatitis
- Myopia
- Basics
- Seniors' Health
- Zoledronic Acid for Injection
- GFR
- Medicaid
- Clinical Trials
- Migration
- Mining
- Clozapine
- Pets and Pet Health
- Clinical Assessment Software Application
- Pimecrolimus Cream 1%
- Hispanic & Latina Women
- Telecommunications
- Hispanic-American Health
- Databases
- Testosterone Gel
- Research

Not Signed In -


